Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions
10.1.2025 15:00:00 CET | Business Wire | Press release
Three new offerings transform delivery, customer communication and checkout services in retail and hospitality settings with proven, measurable ROI
Lenovo today introduced three new retail solutions that combine the best of robotics and artificial intelligence technologies. Premiering at NRF 2025 in New York City, each solution has been field-tested and proven in commercial settings.
Lenovo Retail Content Management Services enables retailers to create, schedule and display digital content across screens store-wide, streamlining multimedia content management and enabling real-time updates and targeted messaging to drive awareness, interest and incremental sales. The complete solution comprises all hardware and software needed, and can be deployed, maintained and managed across multiple locations globally.
A leading food and beverage chain has deployed this content management service across 100+ stores and achieved substantial cost savings from dynamically managed promotional campaigns, reduced use of paper marketing materials, and reduced manpower needed to manage both campaigns and devices.
Lenovo Retail Robotics with Yunji offers automated, independent deliveries of food, guest supplies, room services, and small packages to customers in hotels and malls. By integrating software and services with modular robots, the solution aims to enhance customer satisfaction, improve logistics efficiency, and enable smarter resource management.
This is an advancement to traditional retail robots in three ways. First, this modular design of the robot enables easy customization to a wide range of applications, unlike other robots that are locked into performing a single task. Second, AI, navigation and vision recognition enable high-quality interactions with customers that, combined with reduced delivery times, enable increased customer satisfaction. Third, it collects data as it works, enabling an AI-driven feedback loop that can be integrated into the supply chain, customer service and merchandising decision-making platforms.
The robotics solution, launched in partnership with Yunji Technology, has proven itself in real-world settings. Deployed in a 400-room hotel, for example, it handled more than 90% of guest requests and takeout services, which greatly saved on manpower and time while increasing sales revenue by 20%. Yunji’s robotics solutions are also currently deployed by more than 30,000 hotels, including those of Hilton Hotels & Resorts, Huazhu Group, InterContinental Hotels Group, Jinjiang Group, and Marriott Hotels & Resorts.
“While there is a lot of hype around AI and other technologies, examples of deployment in practical solutions that deliver measurable business outcomes is much rarer,” said Lawrence Yu, General Manager of Global Retail Solutions at Lenovo. “Today’s retailers have never faced greater challenges and have never needed technology to work for them more. Lenovo’s track record in the retail industry, working with some of the world’s biggest name retailers, means we can design, deploy and manage cutting-edge retail and hospitality solutions with low CapEx and high confidence.”
Meeting the AI challenge in retail
Deploying complex IT such as AI securely and responsibly and with maximized demonstrable return on investment remains a significant challenge for businesses in the retail sector.
Lenovo AI Fast Start addresses this challenge and helps retailers prove the business value of use cases on personal AI, enterprise AI and public AI platforms within weeks. It gives access to AI assets, experts and partners that will help retailers rapidly build a Gen AI use case solution securely with their own data and tailor it to their unique needs, speeding progress to full implementation.
A range of additional Lenovo TruScale as a Service offerings enable deployment of AI at scale, with speed and flexibility – and low CapEx costs. Lenovo TruScale Device as a Service (DaaS) provides a comprehensive AI devices portfolio and frees up valuable IT resources with a predictable, scalable subscription-based model. TruScale DaaS allows for quicker upgrades without upfront costs.
Lenovo TruScale Infrastructure as a Service (IaaS) combines the advantages of on-premises infrastructure with the flexibility of a cloud-like experience. Lenovo offers retailers tailored solutions for hybrid and multi-cloud environments, infinite storage, and high-performance computing (HPC). Lenovo’s new TruScale GPU as a Service offering enhances TruScale for HPC with advanced workload orchestration and usage metering, ensuring availability and maximizing productivity of AI-critical GPU resources.
“Although global retail sales are projected to recover in 2025, low consumer confidence is slated to continue plaguing the industry. It behooves retailers to capture this growth opportunity, by optimizing costs and boosting customer satisfaction with AI,” said Lawrence Yu. “Through relying on Lenovo’s deep retail expertise, our industry-leading, scalable hybrid AI approach, and our ability to deliver globally, today’s retailer can considerably improve their chances of sustainable success.”
Visit Lenovo at NRF 2025 exhibiting at booths #3665 and #3877.
For more information on Lenovo Retail Solutions, please visit https://techtoday.lenovo.com/us/en/solutions/retail.
About Lenovo
Lenovo is a US$57 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250110810803/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom